The science at Eitr is driven by a single mantra:
Smaller, Faster, Cheaper
Our Orthogonal Dual-Interacting Nanotherapeutic (ODIN) platform is designed to deliver disruptive, next generation single domain antibody-based technologies for the rapid development of highly potent immunotherapeutics.
We are developing the world’s smallest single domain bispecific to enhance penetration of solid tumors and create a tighter immune synapse between tumor cells and effector cells.
With their unique architecture, ODIN molecules can penetrate the LPS layer of gram-negative bacteria, affording the opportunity to explore new bacterial targets.
Reservoirs of virus can reside deep in organs and tissues, sites that are difficult to reach with classical IgGs. ODIN molecules are designed to penetrate these sites and clear viral infections.